Introducing the EASL Guidelines App – your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Developed by EASL, the European Association for the Study of the Liver, this app is meticulously designed to support healthcare…
The GENIAL project is dedicated to enhancing our understanding of the early stages of alcohol-related hepatocellular carcinoma (ALD-HCC) by integrating clinical hepatology expertise with artificial intelligence (AI). This innovative initiative, as explained by project coordinator Eric Trépo, aims to significantly…
Liver diseases pose a significant global health challenge, with conditions like liver fibrosis often remaining undetected until they reach advanced stages, leading to severe consequences such as cirrhosis and liver cancer. In response to this pressing issue, the LIVERSCREEN project…
Amsterdam, May 2, 2024 – New evidence reveals global underassessment and undertreatment of chronic hepatitis B (HBV), especially among women and Asian minorities in the West, a new study in the Journal of Hepatology, published by Elsevier, details. "In clinical practice…
The liver community mourns the loss of Dr. Stephen Harrison, a visionary in MASLD clinics and clinical research, whose contributions have shaped the current state of the field. Dr. Stephen Harrison was an early clinical researcher who dedicated his career…
EASL is the largest professional body in Europe devoted to liver health. EASL’s overarching goal is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in the field of hepatology. It also advocates at national, European,…
World Liver Day, 19 April 2024 Join us in this important, international campaign
New European project aims to improve tools and advice to prevent chronic liver illnesses. Utrecht, The Netherlands, 05-02-2024: GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in…
After over 20 years of dedicated research and drug development, the FDA has granted approval for the first anti-MASH drug. This marks a pivotal moment for patients battling MASH, whose quality of life and long-term prognosis have been greatly affected…
Liver diseases account for 300,000 deaths in Europe each year. With support from the Innovative Health Initiative, a collaboration of researchers, biotechnology companies and the pharmaceutical industry aim to improve the lives and health of people with hidden liver disease…